Surfactant therapy in neonates with respiratory failure due to haemorrhagic pulmonary oedema

Amizuka, Takasuke; Shimizu, Hiroshi; Niida, Yuichi; Ogawa, Yutaka

doi:10.1007/s00431-003-1276-x

Cited by 62 publications

(54 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…66,79,80,87 However, only a few retrospective and observational reports have documented the benefits from such therapy, and the magnitude of benefit remains to be established. 79,80,87 Such proof is unlikely to materialize soon, because pulmonary hemorrhage is an unpredictable complication, and randomized trials would be difficult to design and implement.…”

Section: Surfactant Replacement For Respiratory Disorders Other Than mentioning

confidence: 99%

Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate

Engle¹

2008

Pediatrics

263

167

View full text Add to dashboard Cite

Respiratory failure secondary to surfactant deficiency is a major cause of morbidity and mortality in preterm infants. Surfactant therapy substantially reduces mortality and respiratory morbidity for this population. Secondary surfactant deficiency also contributes to acute respiratory morbidity in late-preterm and term neonates with meconium aspiration syndrome, pneumonia/sepsis, and perhaps pulmonary hemorrhage; surfactant replacement may be beneficial for these infants. This statement summarizes indications, administration, formulations, and outcomes for surfactant-replacement therapy. The impact of antenatal steroids and continuous positive airway pressure on outcomes and surfactant use in preterm infants is reviewed. Because respiratory insufficiency may be a component of multiorgan dysfunction, preterm and term infants receiving surfactant-replacement therapy should be managed in facilities with technical and clinical expertise to administer surfactant and provide multisystem support.

show abstract

Section: Surfactant Replacement For Respiratory Disorders Other Than mentioning

confidence: 99%

Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate

Engle¹

2008

Pediatrics

263

167

View full text Add to dashboard Cite

show abstract

“…13 Therefore, there was a rationale for the use of surfactant in pulmonary hemorrhage induced RDS. 9,20,21 In our retrospective case series, 13 neonates (72.2%) developed secondary RDS following the onset of severe pulmonary hemorrhage. This indicates that secondary RDS after severe pulmonary hemorrhage is common in VLBW infants and should also be treated properly.…”

Section: Discussionmentioning

confidence: 98%

Short-term Outcome of Pulmonary Hemorrhage in Very-Low-Birth-Weight Preterm Infants

Yen

Wang

Hsieh

et al. 2013

Pediatrics & Neonatology

View full text Add to dashboard Cite

show abstract

“…Amizuka et al, [8] treated 26 out of 27 neonates with PH occurring at 1.5 h after birth with surfactant. Treatment was at 3.0 h after the onset of PH.…”

Section: Discussionmentioning

confidence: 99%

Pulmonary Hemorrhage (PH) in Extremely Low Birth Weight (ELBW) Infants: Successful Treatment with Surfactant

Suryawanshi¹

2015

JCDR

View full text Add to dashboard Cite

Surfactant therapy in neonates with respiratory failure due to haemorrhagic pulmonary oedema

Cited by 62 publications

References 18 publications

Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate

Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate

Short-term Outcome of Pulmonary Hemorrhage in Very-Low-Birth-Weight Preterm Infants

Pulmonary Hemorrhage (PH) in Extremely Low Birth Weight (ELBW) Infants: Successful Treatment with Surfactant

Contact Info

Product

Resources

About